Jia et al. found a significant positive correlation between objective remission rates and TTN mutation frequency in melanoma patients treated with anti-PD-1/PD-L1/CTLA-4 monotherapy (Jia et al., 2019). The gene discussed is PDCD1; the disease is melanoma.